




Phase I à l'Oncopole : le point sur les défis organisationnels



Institut national
de la santé et de la recherche médicale

Sélection des patients (1) : panier ET parapluie



Sélection des patients (2) : au bon moment **ET** en bon état général

- **Inclusion criteria**
 - ≥18 years of age
 - Unresectable local and/or metastatic disease
 - Maximum 2 prior systemic therapies in the metastatic setting
 - ECOG PS 0 or 1
- **Exclusion criteria**
 - Active brain metastases
 - History of active autoimmune disease
 - Active systemic infection
 - HIV infection
 - Requirement for systemic corticosteroids or other immunosuppressive medications





Fig 1. Schema showing the three populations studied. In this analysis, we compared incident cancer cases in the referral region, those referred and considered for a trial, and finally those actually enrolled (bottom box). The deprivation analysis for the incident population was confined to a representative year (10,784 patient cases diagnosed in 2010). Forty-five patients (10.5%) referred were not considered for recruitment to a phase I trial because of clinical deterioration or death in the intervening period.

Activité Recherche Clinique – BEC 2016



Activité Ph Précoce ++





- 133 inclusions Ph I et I-II (vs 85 en 2015) : +35 %
- 25 inclusions Etude Pilote PK /PD (stable)
- 203 inclusions Ph II (vs 112 en 2015) : + 80 %
- 260 inclusions Phase III (vs 201 en 2015) : + 30%


Pathologies ++ : urologie, neuro, mélanome, toute tumeurs solides : + 50 % incl

Immunothérapie : 39 essais en 2016 – 296 inclusions

Precision Immunotherapy



Schumacher T et al. Science 2015.



INSTITUT UNIVERSITAIRE DU CANCER DE TOULOUSE

Oncopole

